Pepaxti study supports use in wider myeloma population
20th May 2026 Uncategorised 0
Phase 2 bridge data show consistent outcomes in patients with impaired kidney function

More: Pepaxti study supports use in wider myeloma population
Source: News
Phase 2 bridge data show consistent outcomes in patients with impaired kidney function

More: Pepaxti study supports use in wider myeloma population
Source: News
© 1994 - 2026 B.M. Pharmaceuticals